6.54
-0.225(-3.33%)
Currency In USD
| Previous Close | 6.76 |
| Open | 6.74 |
| Day High | 6.9 |
| Day Low | 6.51 |
| 52-Week High | 17.14 |
| 52-Week Low | 6.26 |
| Volume | 462,082 |
| Average Volume | 1.5M |
| Market Cap | 662.4M |
| PE | -10.05 |
| EPS | -0.65 |
| Moving Average 50 Days | 7.92 |
| Moving Average 200 Days | 12.17 |
| Change | -0.23 |
If you invested $1000 in Day One Biopharmaceuticals, Inc. (DAWN) since IPO date, it would be worth $278.09 as of May 09, 2025 at a share price of $6.535. Whereas If you bought $1000 worth of Day One Biopharmaceuticals, Inc. (DAWN) shares 3 years ago, it would be worth $844.32 as of May 09, 2025 at a share price of $6.535.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
GlobeNewswire Inc.
Apr 22, 2025 12:30 PM GMT
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
GlobeNewswire Inc.
Feb 11, 2025 1:30 PM GMT
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
Preliminary 2024 OJEMDA™ (tovorafenib) net product revenue of approximately $57.2 million (unaudited) First dose cohort cleared in Phase 1a/b clinical trial of DAY301 (PTK7-targeted ADC) Ended 2024 with approximately $531.7 million in cash, cash equi